Gilead is paying $1,675 million upfront — with $500 million more in contingent milestones — for a subcutaneous BCMAxCD3 T cell engager that has never generated commercial revenue, and it is doing so through a structure that leaves its long-standing partner Lakefront Biotherapeutics holding the Phase 1/2 operational reins while Gilead controls all registrational work and global commercialization. That division of labor is not incidental. It is a deliberate bet that Lakefront’s clinical execution capability is worth subsidizing, and that gamgertamig’s mechanism — rapid, deep plasma cell and B cell depletion from a limited treatment course — can translate the success of BCMAxCD3 engagers already approved in multiple myeloma into severe antibody-mediated orphan diseases like autoimmune hemolytic anemia and immune thrombocytopenia.
The financial architecture rewards both sides asymmetrically in time. Gilead absorbs the commercialization risk entirely — and foots that bill alone — but captures 100% of revenue outside Keymed’s Greater China territories. Lakefront, for its part, walks away from the transaction with tiered royalties of 20%–23% on net sales, three additional preclinical autoimmune programs carrying a $75 million per-program Gilead opt-in at clinical proof-of-concept, and a projected year-end 2026 cash balance of approximately €2 billion — down from roughly €3 billion at the close of 2025 but still a war chest that the renegotiated OLCA now lets Lakefront deploy independently, including up to €150 million in share buybacks. The deal also transforms what was formerly Galapagos from a company that spent years searching for its post-filgotinib identity into one with a defined clinical engine centered on a single high-conviction asset.
Gamgertamig’s FDA Fast Track and Orphan Drug Designations for both AIHA and ITP clear the path toward registrational studies as early as 2027. The strategic logic sits inside a broader Gilead thesis — shifting inflammation treatment from chronic suppression toward durable immune reset — that also underlies its existing cell therapy infrastructure. Whether that thesis holds depends entirely on whether deep plasma cell depletion in these indications produces the remission durability the mechanism promises in theory, or whether patients simply rebuild pathogenic antibody-producing cells over time.
The single number worth watching is the Phase 2 durability readout. Registrational design hinges on how long remission actually lasts after a limited treatment course; if that window is shorter than the label claim requires, the $500 million in milestone payments stays locked and the royalty tiers that define Lakefront’s revenue model compress accordingly.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
